Literature DB >> 17934070

Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells.

Unn-Merete Fagerli1, Randi U Holt, Toril Holien, Thea K Vaatsveen, Fenghuang Zhan, Kjartan W Egeberg, Bart Barlogie, Anders Waage, Harald Aarset, Hong Yan Dai, John D Shaughnessy, Anders Sundan, Magne Børset.   

Abstract

Multiple myeloma (MM) is characterized by accumulation and dissemination of malignant plasma cells (PCs) in the bone marrow (BM). Gene expression profiling of 2 MM cell lines (OH-2 and IH-1) indicated that expression of PRL-3, a metastasis-associated tyrosine phosphatase, was induced by several mitogenic cytokines. Cytokine-driven PRL-3 expression could be shown in several myeloma cell lines at both the mRNA and protein levels. There was significantly higher expression of the PRL-3 gene in PCs from patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma (SMM), and myeloma than in PCs from healthy persons. Among 7 MM subgroups identified by unsupervised hierarchical cluster analysis, PRL-3 gene expression was significantly higher in the 3 groups denoted as "proliferation," "low bone disease," and "MMSET/FGFR3." PRL-3 protein was detected in 18 of 20 BM biopsies from patients with MM. Silencing of the PRL-3 gene by siRNA reduced cell migration in the MM cell line INA-6, but had no detectable effect on proliferation and cell-cycle phase distribution of the cells. In conclusion, PRL-3 is a gene product specifically expressed in malignant plasma cells and may have a role in migration of these cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17934070      PMCID: PMC2200854          DOI: 10.1182/blood-2007-07-101139

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  56 in total

Review 1.  Rho GTPases in cell biology.

Authors:  Sandrine Etienne-Manneville; Alan Hall
Journal:  Nature       Date:  2002-12-12       Impact factor: 49.962

Review 2.  Plasma-cell homing.

Authors:  Eric J Kunkel; Eugene C Butcher
Journal:  Nat Rev Immunol       Date:  2003-10       Impact factor: 53.106

3.  Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma.

Authors:  Yazan Alsayed; Hai Ngo; Judith Runnels; Xavier Leleu; Ujjal K Singha; Costas M Pitsillides; Joel A Spencer; Teresa Kimlinger; Joanna M Ghobrial; Xiaoying Jia; Ganwei Lu; Michael Timm; Ashok Kumar; Daniel Côté; Israel Veilleux; Karen E Hedin; G David Roodman; Thomas E Witzig; Andrew L Kung; Teru Hideshima; Kenneth C Anderson; Charles P Lin; Irene M Ghobrial
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

4.  PRL-3 down-regulates PTEN expression and signals through PI3K to promote epithelial-mesenchymal transition.

Authors:  Haihe Wang; Samantha Yiling Quah; Jing Ming Dong; Edward Manser; Jing Ping Tang; Qi Zeng
Journal:  Cancer Res       Date:  2007-04-01       Impact factor: 12.701

5.  Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma.

Authors:  Y Shou; M L Martelli; A Gabrea; Y Qi; L A Brents; A Roschke; G Dewald; I R Kirsch; P L Bergsagel; W M Kuehl
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

6.  A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

Authors:  John D Shaughnessy; Fenghuang Zhan; Bart E Burington; Yongsheng Huang; Simona Colla; Ichiro Hanamura; James P Stewart; Bob Kordsmeier; Christopher Randolph; David R Williams; Yan Xiao; Hongwei Xu; Joshua Epstein; Elias Anaissie; Somashekar G Krishna; Michele Cottler-Fox; Klaus Hollmig; Abid Mohiuddin; Mauricio Pineda-Roman; Guido Tricot; Frits van Rhee; Jeffrey Sawyer; Yazan Alsayed; Ronald Walker; Maurizio Zangari; John Crowley; Bart Barlogie
Journal:  Blood       Date:  2006-11-14       Impact factor: 22.113

7.  Profiling of Hodgkin's lymphoma cell line L1236 and germinal center B cells: identification of Hodgkin's lymphoma-specific genes.

Authors:  Ines Schwering; Andreas Bräuninger; Verena Distler; Julia Jesdinsky; Volker Diehl; Martin-Leo Hansmann; Klaus Rajewsky; Ralf Küppers
Journal:  Mol Med       Date:  2003 Mar-Apr       Impact factor: 6.354

8.  PRL-3 and PRL-1 promote cell migration, invasion, and metastasis.

Authors:  Qi Zeng; Jing-Ming Dong; Ke Guo; Jie Li; Hui-Xian Tan; Vicki Koh; Catherine J Pallen; Edward Manser; Wanjin Hong
Journal:  Cancer Res       Date:  2003-06-01       Impact factor: 12.701

Review 9.  Selecting protein tyrosine phosphatases as drug targets.

Authors:  Rob Hooft van Huijsduijnen; Agnes Bombrun; Dominique Swinnen
Journal:  Drug Discov Today       Date:  2002-10-01       Impact factor: 7.851

10.  Gene profiling of a myeloma cell line reveals similarities and unique signatures among IL-6 response, N-ras-activating mutations, and coculture with bone marrow stromal cells.

Authors:  Paula A Croonquist; Michael A Linden; Fangyi Zhao; Brian G Van Ness
Journal:  Blood       Date:  2003-06-05       Impact factor: 22.113

View more
  45 in total

Review 1.  Targeting protein tyrosine phosphatases for anticancer drug discovery.

Authors:  Latanya M Scott; Harshani R Lawrence; Saïd M Sebti; Nicholas J Lawrence; Jie Wu
Journal:  Curr Pharm Des       Date:  2010-06       Impact factor: 3.116

2.  Protein-tyrosine phosphatase 4A3 (PTP4A3) promotes vascular endothelial growth factor signaling and enables endothelial cell motility.

Authors:  Mark W Zimmerman; Kelley E McQueeney; Jeffrey S Isenberg; Bruce R Pitt; Karla A Wasserloos; Gregg E Homanics; John S Lazo
Journal:  J Biol Chem       Date:  2014-01-08       Impact factor: 5.157

Review 3.  Regulatory Mechanisms and Novel Therapeutic Targeting Strategies for Protein Tyrosine Phosphatases.

Authors:  Zhi-Hong Yu; Zhong-Yin Zhang
Journal:  Chem Rev       Date:  2017-05-25       Impact factor: 60.622

4.  Novel Anticancer Agents Based on Targeting the Trimer Interface of the PRL Phosphatase.

Authors:  Yunpeng Bai; Zhi-Hong Yu; Sijiu Liu; Lujuan Zhang; Ruo-Yu Zhang; Li-Fan Zeng; Sheng Zhang; Zhong-Yin Zhang
Journal:  Cancer Res       Date:  2016-06-20       Impact factor: 12.701

5.  Expression of phosphatase of regenerating liver-3 in squamous cell carcinoma of the cervix.

Authors:  Yaxi Ma; Baizhou Li
Journal:  Med Oncol       Date:  2010-04-03       Impact factor: 3.064

Review 6.  Phosphatase of regenerating liver in hematopoietic stem cells and hematological malignancies.

Authors:  Michihiro Kobayashi; Sisi Chen; Rui Gao; Yunpeng Bai; Zhong-Yin Zhang; Yan Liu
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

7.  B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells.

Authors:  Matthieu Mahévas; Pauline Patin; François Huetz; Marc Descatoire; Nicolas Cagnard; Christine Bole-Feysot; Simon Le Gallou; Mehdi Khellaf; Olivier Fain; David Boutboul; Lionel Galicier; Mikael Ebbo; Olivier Lambotte; Mohamed Hamidou; Philippe Bierling; Bertrand Godeau; Marc Michel; Jean-Claude Weill; Claude-Agnès Reynaud
Journal:  J Clin Invest       Date:  2012-12-17       Impact factor: 14.808

Review 8.  Phosphatase of regenerating liver: a novel target for cancer therapy.

Authors:  Amanda M Campbell; Zhong-Yin Zhang
Journal:  Expert Opin Ther Targets       Date:  2014-03-01       Impact factor: 6.902

9.  High expression of BCL3 in human myeloma cells is associated with increased proliferation and inferior prognosis.

Authors:  Anne-Tove Brenne; Unn-Merete Fagerli; John D Shaughnessy; Thea Kristin Våtsveen; Torstein Baade Rø; Hanne Hella; Fenghuang Zhan; Bart Barlogie; Anders Sundan; Magne Børset; Anders Waage
Journal:  Eur J Haematol       Date:  2009-01-13       Impact factor: 2.997

10.  PRL-3 promotes the motility, invasion, and metastasis of LoVo colon cancer cells through PRL-3-integrin beta1-ERK1/2 and-MMP2 signaling.

Authors:  Lirong Peng; Xiaofang Xing; Weijun Li; Like Qu; Lin Meng; Shenyi Lian; Beihai Jiang; Jian Wu; Chengchao Shou
Journal:  Mol Cancer       Date:  2009-11-24       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.